Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • CIRM Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • CIRM Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

Tissue engineered cartilage from autologous, dermis-isolated, adult, stem (DIAS) cells

  • Post author:
  • Post published:November 3, 2025
  • Post category:

This study addresses the cartilage defects resulting from injuries or from wear-and-tear that can eventually degenerate to osteoarthritis. This is a significant problem that impacts millions and costs in excess…

Continue ReadingTissue engineered cartilage from autologous, dermis-isolated, adult, stem (DIAS) cells

Multiple Sclerosis therapy: Human Pluripotent Stem Cell-Derived Neural Progenitor Cells

  • Post author:
  • Post published:November 3, 2025
  • Post category:

Multiple Sclerosis (MS) is a disease of the central nervous system (CNS) caused by inflammation and loss of cells that produce myelin, which normally insulates and protects nerve cells. MS…

Continue ReadingMultiple Sclerosis therapy: Human Pluripotent Stem Cell-Derived Neural Progenitor Cells

Targeting Stem Cells to Enhance Remyelination in the Treatment of Multiple Sclerosis

  • Post author:
  • Post published:November 3, 2025
  • Post category:

Multiple sclerosis (MS) is an autoimmune disease in which the myelin sheath that insulates neurons is destroyed, resulting in loss of proper neuronal function. Existing treatments for MS are based…

Continue ReadingTargeting Stem Cells to Enhance Remyelination in the Treatment of Multiple Sclerosis

Human ES cell-derived MGE inhibitory interneuron transplantation for spinal cord injury

  • Post author:
  • Post published:November 3, 2025
  • Post category:

Transplantation of neuronal precursors into the central nervous system offers great promise for the treatment of neurological disorders including spinal cord injury (SCI). Among the most significant consequences of SCI…

Continue ReadingHuman ES cell-derived MGE inhibitory interneuron transplantation for spinal cord injury

Molecules to Correct Aberrant RNA Signature in Human Diseased Neurons

  • Post author:
  • Post published:November 3, 2025
  • Post category:

Approximately 5,600 people in the U.S. are diagnosed with ALS each year. The incidence of ALS is two per 100,000 people, and it is estimated that as many as 30,000…

Continue ReadingMolecules to Correct Aberrant RNA Signature in Human Diseased Neurons

Regeneration of Functional Human Corneal Epithelial Progenitor Cells

  • Post author:
  • Post published:November 3, 2025
  • Post category:

Over 3.2 million people worldwide are bilateral blind from corneal diseases. Limbal stem cell deficiency (LSCD) has been recognized as a major cause, either primary or secondary, of significant visual…

Continue ReadingRegeneration of Functional Human Corneal Epithelial Progenitor Cells

Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy

  • Post author:
  • Post published:November 3, 2025
  • Post category:

Many neurological disorders are characterized by an imbalance between excitation and inhibition. Our ultimate goal: to develop a cell-based therapy to modulate aberrant brain activity in the treatment of these…

Continue ReadingInhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy

Liver Cell Transplantation

  • Post author:
  • Post published:November 3, 2025
  • Post category:

Because there is still considerable morbidity and mortality associated with the process of whole liver transplantation, and because more than a thousand people die each year while on the liver…

Continue ReadingLiver Cell Transplantation

Stem Cell Therapy for Duchenne Muscular Dystrophy

  • Post author:
  • Post published:November 3, 2025
  • Post category:

Duchenne muscular dystrophy (DMD) is the most common and serious form of muscular dystrophy. One out of every 3500 boys is born with the disorder, and it is invariably fatal.…

Continue ReadingStem Cell Therapy for Duchenne Muscular Dystrophy

Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury

  • Post author:
  • Post published:November 3, 2025
  • Post category:

Traumatic brain injury (TBI) affects 1.4 million Americans a year; 175,000 in California. When the brain is injured, nerve cells near the site of injury die due to the initial…

Continue ReadingNeural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury
  • Go to the previous page
  • 1
  • …
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us